Sitryx Therapeutics Receives FDA Clearance for Phase 1b Trial of SYX-5219 in Atopic Dermatitis

Sitryx Therapeutics, a clinical-stage biopharmaceutical company developing novel oral therapies to restore immune balance in autoimmune and inflammatory diseases, announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for SYX-5219. This approval supports the initiation of a Phase 1b trial in adults with moderate to severe atopic dermatitis (AD) in the United States, expected to start in Q1 2026.

About SYX-5219

SYX-5219 is a first-in-class, oral, disease-modifying, anti-inflammatory therapy that targets pyruvate kinase M2 (PKM2), a key enzyme regulating cell metabolism. By modulating PKM2, SYX-5219:

• Alters T lymphocyte and mast cell function
• Offers a broad anti-itch effect
• Supports skin barrier repair
• Has potential to drive sustained disease remission in atopic dermatitis and other autoimmune conditions

Preclinical studies have demonstrated that SYX-5219 reduces inflammatory markers and enhances barrier repair, supporting its potential as a disease-modifying therapy.

Current Clinical Development

• Phase 1a trial: Evaluating safety, tolerability, and pharmacokinetics in healthy volunteers in the UK, under approval from the MHRA (Medicines and Healthcare products Regulatory Agency)
• Phase 1b trial: Will assess clinical and biological effects in adults with moderate to severe atopic dermatitis in the US

“The US FDA’s clearance of our IND application represents a pivotal milestone in the clinical development of SYX-5219. We look forward to generating data that will guide the next stage of development and provide life-changing benefits to patients.”

• Iain Kilty, CEO of Sitryx.

“Atopic dermatitis affects over 200 million people worldwide. SYX-5219 offers a novel oral approach with the potential for durable disease remission, and the Phase 1b study will provide critical insights into its effects in patients.”

• Ravi Rao, CMO of Sitryx.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!